284 related articles for article (PubMed ID: 14586540)
21. Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement.
Braida D; Limonta V; Pegorini S; Zani A; Guerini-Rocco C; Gori E; Sala M
Psychopharmacology (Berl); 2007 Mar; 190(4):441-8. PubMed ID: 17219220
[TBL] [Abstract][Full Text] [Related]
22. Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects.
MacLean KA; Johnson MW; Reissig CJ; Prisinzano TE; Griffiths RR
Psychopharmacology (Berl); 2013 Mar; 226(2):381-92. PubMed ID: 23135605
[TBL] [Abstract][Full Text] [Related]
23. Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents.
Walentiny DM; Vann RE; Warner JA; King LS; Seltzman HH; Navarro HA; Twine CE; Thomas BF; Gilliam AF; Gilmour BP; Carroll FI; Wiley JL
Psychopharmacology (Berl); 2010 Jun; 210(2):275-84. PubMed ID: 20354680
[TBL] [Abstract][Full Text] [Related]
24. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
Solinas M; Goldberg SR
Psychopharmacology (Berl); 2005 Jun; 179(4):804-12. PubMed ID: 15619107
[TBL] [Abstract][Full Text] [Related]
25. Systemic effects of E-2078, a stabilized dynorphin A(1-8) analog, in rhesus monkeys.
Butelman ER; Vivian JA; Yu J; Kreek MJ; Woods JH
Psychopharmacology (Berl); 1999 Apr; 143(2):190-6. PubMed ID: 10326782
[TBL] [Abstract][Full Text] [Related]
26. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice.
Capasso R; Borrelli F; Zjawiony J; Kutrzeba L; Aviello G; Sarnelli G; Capasso F; Izzo AA
Neurogastroenterol Motil; 2008 Feb; 20(2):142-8. PubMed ID: 17931335
[TBL] [Abstract][Full Text] [Related]
27. Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology.
Grundmann O; Phipps SM; Zadezensky I; Butterweck V
Planta Med; 2007 Aug; 73(10):1039-46. PubMed ID: 17628834
[TBL] [Abstract][Full Text] [Related]
28. Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.
Polepally PR; White K; Vardy E; Roth BL; Ferreira D; Zjawiony JK
Bioorg Med Chem Lett; 2013 May; 23(10):2860-2. PubMed ID: 23587424
[TBL] [Abstract][Full Text] [Related]
29. Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward.
Braida D; Limonta V; Capurro V; Fadda P; Rubino T; Mascia P; Zani A; Gori E; Fratta W; Parolaro D; Sala M
Biol Psychiatry; 2008 Feb; 63(3):286-92. PubMed ID: 17920565
[TBL] [Abstract][Full Text] [Related]
30. Salvinorin A: a novel and highly selective kappa-opioid receptor agonist.
Yan F; Roth BL
Life Sci; 2004 Oct; 75(22):2615-9. PubMed ID: 15369697
[TBL] [Abstract][Full Text] [Related]
31. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine.
Negus SS; Burke TF; Medzihradsky F; Woods JH
J Pharmacol Exp Ther; 1993 Nov; 267(2):896-903. PubMed ID: 8246165
[TBL] [Abstract][Full Text] [Related]
32. Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.
Cunningham CW; Rothman RB; Prisinzano TE
Pharmacol Rev; 2011 Jun; 63(2):316-47. PubMed ID: 21444610
[TBL] [Abstract][Full Text] [Related]
33. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum.
Capasso R; Borrelli F; Capasso F; Siebert DJ; Stewart DJ; Zjawiony JK; Izzo AA
Neurogastroenterol Motil; 2006 Jan; 18(1):69-75. PubMed ID: 16371085
[TBL] [Abstract][Full Text] [Related]
34. Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.
Johnson MW; MacLean KA; Caspers MJ; Prisinzano TE; Griffiths RR
J Psychopharmacol; 2016 Apr; 30(4):323-9. PubMed ID: 26880225
[TBL] [Abstract][Full Text] [Related]
35. The antinociceptive effect of salvinorin A in mice.
John TF; French LG; Erlichman JS
Eur J Pharmacol; 2006 Sep; 545(2-3):129-33. PubMed ID: 16905132
[TBL] [Abstract][Full Text] [Related]
36. Discriminative stimulus effects of the nonpeptidic delta-opioid agonist SNC80 in rhesus monkeys.
Brandt MR; Negus SS; Mello NK; Furness MS; Zhang X; Rice KC
J Pharmacol Exp Ther; 1999 Sep; 290(3):1157-64. PubMed ID: 10454490
[TBL] [Abstract][Full Text] [Related]
37. Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist.
McCurdy CR; Sufka KJ; Smith GH; Warnick JE; Nieto MJ
Pharmacol Biochem Behav; 2006 Jan; 83(1):109-13. PubMed ID: 16434091
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues.
Lee DY; He M; Liu-Chen LY; Wang Y; Li JG; Xu W; Ma Z; Carlezon WA; Cohen B
Bioorg Med Chem Lett; 2006 Nov; 16(21):5498-502. PubMed ID: 16945525
[TBL] [Abstract][Full Text] [Related]
39. Psychopharmacology of the hallucinogenic sage Salvia divinorum.
Prisinzano TE
Life Sci; 2005 Dec; 78(5):527-31. PubMed ID: 16213533
[TBL] [Abstract][Full Text] [Related]
40. Learning and memory impairment induced by salvinorin A, the principal ingredient of Salvia divinorum, in wistar rats.
Braida D; Donzelli A; Martucci R; Capurro V; Sala M
Int J Toxicol; 2011 Dec; 30(6):650-61. PubMed ID: 21960665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
